PMID- 28960263
OWN - NLM
STAT- MEDLINE
DCOM- 20190611
LR  - 20220410
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 124
IP  - 2
DP  - 2018 Jan 15
TI  - Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small 
      cell lung cancer: A systematic analysis of the literature.
PG  - 271-277
LID - 10.1002/cncr.31043 [doi]
AB  - BACKGROUND: Monoclonal antibodies against programmed cell death protein 1 (PD-1) 
      and programmed death ligand 1 (PD-L1) are effective therapies in patients with 
      non-small cell lung cancer (NSCLC). Herein, the authors performed a systematic 
      review investigating differences in the toxicities of PD-1 and PD-L1 inhibitors. 
      METHODS: An electronic literature search was performed of public databases 
      (MEDLINE, Excerpta Medica dataBASE [EMBASE], and Cochrane) and conference 
      proceedings for trials using PD-1 inhibitors (nivolumab and pembrolizumab) and 
      PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) in patients with NSCLC. 
      A formal systematic analysis was conducted with Comprehensive Meta-Analysis 
      software (version 2.2). Clinical and demographic characteristics, response, and 
      toxicity data were compared between both groups. RESULTS: A total of 23 studies 
      reported between 2013 and 2016 were eligible for analysis. The total number of 
      patients evaluated for toxicities was 3284 patients in the PD-1 group and 2460 
      patients in the PD-L1 group. The baseline patient characteristics of the 2 groups 
      were similar, although there was a trend toward increased squamous histology in 
      the group treated with PD-L1 (32% vs 25%; P = .6). There was no difference in 
      response rate noted between PD-1 (19%) and PD-L1 (18.6%) inhibitors (P = .17). 
      The incidence of overall adverse events (AEs) was comparable between the PD-1 and 
      PD-L1 inhibitors (64% [95% confidence interval (95% CI), 63%-66%] vs 66% [95% CI, 
      65%-69%]; P = .8). Fatigue was the most frequently reported AE with both classes 
      of drugs. Patients treated with PD-1 inhibitors were found to have a slightly 
      increased rate of immune-related AEs (16% [95% CI, 14%-17%] vs 11% [95% CI, 
      10%-13%]; P = .07) and pneumonitis (4% [95% CI, 3%-5%] vs 2% [95% CI, 1%-3%]; P = 
      .01) compared with patients who received PD-L1 inhibitors. CONCLUSIONS: In this 
      systematic review involving 5744 patients with NSCLC, the toxicity and efficacy 
      profiles of PD-1 and PD-L1 inhibitors appear to be similar. Cancer 
      2018;124:271-7. (c) 2017 American Cancer Society.
CI  - (c) 2017 American Cancer Society.
FAU - Pillai, Rathi N
AU  - Pillai RN
AD  - Department of Hematology and Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Behera, Madhusmita
AU  - Behera M
AD  - Department of Hematology and Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Owonikoko, Taofeek K
AU  - Owonikoko TK
AD  - Department of Hematology and Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Kamphorst, Alice O
AU  - Kamphorst AO
AD  - Emory Vaccine Center, Department of Microbiology and Immunology, Emory 
      University, Atlanta, Georgia.
FAU - Pakkala, Suchita
AU  - Pakkala S
AD  - Department of Hematology and Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Belani, Chandra P
AU  - Belani CP
AD  - Pennsylvania University, Penn State Hershey Cancer Institute, Hershey, 
      Pennsylvania.
FAU - Khuri, Fadlo R
AU  - Khuri FR
AUID- ORCID: 0000-0003-4171-3392
AD  - Department of Hematology and Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
FAU - Ahmed, Rafi
AU  - Ahmed R
AD  - Emory Vaccine Center, Department of Microbiology and Immunology, Emory 
      University, Atlanta, Georgia.
FAU - Ramalingam, Suresh S
AU  - Ramalingam SS
AUID- ORCID: 0000-0002-0757-3106
AD  - Department of Hematology and Oncology, Winship Cancer Institute, Emory 
      University, Atlanta, Georgia.
LA  - eng
GR  - P30 CA138292/CA/NCI NIH HHS/United States
GR  - U10 CA180864/CA/NCI NIH HHS/United States
GR  - U10 CA180950/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Systematic Review
DEP - 20170928
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 52CMI0WC3Y (atezolizumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
CIN - J Thorac Dis. 2018 Nov;10(Suppl 33):S4034-S4037. PMID: 30631548
CIN - J Thorac Dis. 2018 Nov;10(Suppl 33):S4065-S4068. PMID: 30631556
CIN - J Thorac Dis. 2018 Nov;10(Suppl 33):S4069-S4072. PMID: 30631557
CIN - J Thorac Dis. 2018 Nov;10(Suppl 33):S4082-S4084. PMID: 30631561
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - B7-H1 Antigen/*antagonists & inhibitors
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
PMC - PMC5761314
MID - NIHMS928341
OTO - NOTNLM
OT  - adverse events
OT  - immune checkpoint inhibitors
OT  - immune-related adverse events
OT  - non-small cell lung cancer (NSCLC)
COIS- Disclosures: None of the authors have any conflicts of interest to report.
EDAT- 2017/09/30 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/01/15
CRDT- 2017/09/30 06:00
PHST- 2017/03/13 00:00 [received]
PHST- 2017/08/08 00:00 [revised]
PHST- 2017/08/14 00:00 [accepted]
PHST- 2017/09/30 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2017/09/30 06:00 [entrez]
PHST- 2019/01/15 00:00 [pmc-release]
AID - 10.1002/cncr.31043 [doi]
PST - ppublish
SO  - Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.